Cargando…
Value of drug level testing and antibody assays in optimising biological therapy
Autores principales: | Vermeire, Séverine, Gils, Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533399/ https://www.ncbi.nlm.nih.gov/pubmed/23293739 http://dx.doi.org/10.1136/flgastro-2012-100241 |
Ejemplares similares
-
Impact of therapeutic drug level monitoring on outcomes of patients with Crohn’s disease treated with Infliximab: real world data from a retrospective single centre cohort study
por: Kamperidis, Nikolaos, et al.
Publicado: (2019) -
Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
por: Shields, Stephanie, et al.
Publicado: (2020) -
Clinico‐metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases
por: Bohlok, Ali, et al.
Publicado: (2021) -
Faecal immunochemical testing (FIT) in symptomatic patients: what are we missing?
por: Farrugia, Alexia, et al.
Publicado: (2019) -
An urgent need to institute COVID-19 testing in patients with IBD experiencing flares
por: Quraishi, Mohammed Nabil, et al.
Publicado: (2020)